FAQs & How to use this site
Home | About Us | Contact Us
The Front Line

 

The Front Line: Charles D. Blanke, MD, SWOG Chair
ABOUT

PREVIOUS POSTS October 2017

September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

SWOG Study Shines at GI Symposium

January 27, 2017 - Promising SWOG research results have been rolling in recently. Here’s one I’m particularly excited about. Investigator Dr. Scott Kopetz of MD Anderson has spent nearly a decade studying BRAF-mutant metastatic colorectal cancer and effective ways to treat it. His exploratory and subsequent work – most recently conducted through SWOG – looks like it will bear fruit.

Last week at the 2017 Gastrointestinal Cancers Symposium, Kopetz reported that patients with this classically treatment-resistant form of colorectal cancer had significantly better outcomes when the BRAF-inhibitor vemurafenib is added to a standard chemotherapy treatment. This really is a big deal; it appears to be the first time anyone has identified an effective treatment for this deadly cancer.

Dr. Howard Hochster, my successor overseeing the GI committee and the senior member of the study team, said this about the Kopetz talk at the symposium: “Excellent presentation. Highly well received and hopefully will set a new standard of care.”

The Kopetz study, S1406, enrolled 106 patients, notable even for that number. Roughly half received the investigational regimen of vemurafenib plus irinotecan and cetuximab. The rest received only the chemobiologic.

Results were striking. Patients who got the typical two-drug combination had a progression-free survival time of two months. Patients who received vemurafenib had a median PFS of 4.4 months. S1406 results also demonstrated a 67% objective response rate, compared with 22% getting the standard treatment.

You can view all the details on the trial here. I congratulate Dr. Kopetz and the S1406 team. It’s great to see a hypothesis move through a Phase I study and blossom into a randomized trial. In the coming months, survival data from S1406 will come in and show whether or not this study changes the standard of care. While we all know clinical cancer research can be long and slow, S1406 might truly pay off for our patients.

 
     
SWOG Logo Disclaimer | Copyright ©2000-2017 SWOG. All rights reserved.
Design by nuMedia Group Inc. | Hosting by WorldPost Technologies, Inc.
SWOG is FISMA CertifiedSWOG is FISMA Certified